- Home
- SWKS vs QGEN Comparison
SWKS vs QGEN Comparison
Compare SWKS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWKS | QGEN |
|---|---|---|
| Founded | 1962 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.0B |
| IPO Year | 1995 | 1998 |
Fundamental Metrics
Financial Performance| Metric | SWKS | QGEN |
|---|---|---|
| Price | $88.68 | $43.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $70.38 | $45.76 |
| AVG Volume (30 Days) | ★ 6.6M | 2.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | 4.53% | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $4,086,900,000.00 | N/A |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | $3.06 | $5.71 |
| P/E Ratio | $92.24 | ★ $24.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.93 | $32.53 |
| 52 Week High | $92.30 | $57.82 |
Technical Indicators
Market Signals| Indicator | SWKS | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 55.20 |
| Support Level | $54.32 | $41.14 |
| Resistance Level | $92.30 | $44.72 |
| Average True Range (ATR) | 5.53 | 0.94 |
| MACD | 1.57 | -0.00 |
| Stochastic Oscillator | 85.83 | 62.99 |
Price Performance
Historical ComparisonAbout SWKS Skyworks Solutions Inc.
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).